SYNTIS BIO INC

Syntis Bio is a clinical-stage biopharmaceutical company developing transformative therapies that harness the small intestine, either by creating a transient protective barrier or by markedly enhancing drug efficacy, enabling oral treatments for patients with serious and underserved conditions. Syntis Bio began with a moment of inspiration in the Langer and Traverso Labs at MIT after being tasked by the Bill & Melinda Gates Foundation to enhance the bioavailability of oral therapies for children in low-resource settings. SYNT, or SYNtheticTissue-lining, harnesses mussel-inspired polymer chemistry to deliver a safe, transient polymer coating to specific tissues within the GI tract and can sustain therapeutic activity in the small intestine for up to 24 hours.